Drug Profile
Naproxen topical - CeNeS
Alternative Names: RS 3540 topical - CeNeS; RS-3540Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator CeNeS Pharmaceuticals
- Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 27 Oct 2004 Discontinued - Clinical-Phase-Unknown for Inflammation in United Kingdom (Topical)
- 16 Dec 1999 Core Group has merged with CeNeS Limited to form CeNeS Pharmaceuticals
- 25 Jul 1999 Clinical trials due to begin in the US in late 1999/early 2000